Initiating GLP-1 Drugs May Slightly Raise Depression Risk
Patients with T2D and overweight/obesity starting GLP-1 therapy may experience a small but statistically significant increase in the risk for depression compared with those starting SGLT2 inhibitors. Medscape Medical News
Dr Megan Rossi and Gemma Ogston on how to heal your gut and eat 30 plants a week
Gut health is one of the biggest trends of the year. It’s a catch-all term that’s been used to sell supplements, spook people about their diets and encourage disordered eating. But it’s also prompted a spike in sales of gut-friendly foods, an uptick in body literacy and an arguably healthier population. Leading gut health expert […]
Relative efficacy of GLP‐1 and GLP‐1/GIP receptor agonists in the prevention of alcohol‐use disorders using a target trial emulation approach
Abstract Aims There is growing evidence that the GLP-1 system is implicated in alcohol and other substance use disorders, and that GLP-1-based therapies may have therapeutic relevance in alcohol use disorder (AUD). We aimed to determine the impact of GLP-1 based therapies on incident AUDs in a real-world setting in patients with T2D. Material and […]
Gut Delivery of Pentameric GLP-1 Using Genetically Engineered Bacillus subtilis for Diabetes and Obesity Treatment
Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and {beta}-cell dysfunction. Glucagon-like peptide-1 (GLP-1) has emerged as a pivotal therapeutic target due to its roles in promoting insulin secretion, regulating appetite, and enhancing lipid metabolism. However, GLP-1-based therapies face significant challenges, including high production costs, complex delivery methods, and […]
New ‘unusual’ side effect of weight-loss drugs becoming more common, research suggests
GLP-1 drugs may interfere with medical imaging, leading to unnecessary tests, researchers have found
GLP-1 receptor agonists linked to altered patterns on FDG PET-CT scans
The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM’25) has revealed.
2025 Proteomics Breakthroughs
Proteomics—a term first coined in the mid-1990s—refers to the study of the complete set of proteins expressed in a cell, tissue, or organism. In contrast to genomics and transcriptomics, proteomics is particularly well-suited for capturing dynamic events, including such things as protein degradation and post-translational modifications. While proteomics has generally lagged behind genomics in scale […]
Top 10 Spatial Biology Companies of 2025
Proteomics—a term first coined in the mid-1990s—refers to the study of the complete set of proteins expressed in a cell, tissue, or organism. In contrast to genomics and transcriptomics, proteomics is particularly well-suited for capturing dynamic events, including such things as protein degradation and post-translational modifications. While proteomics has generally lagged behind genomics in scale […]
GLP-1 agonists pose emerging challenge for PET-CT imaging, study finds
The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM 2025) has revealed.
Felix eyes preventative health market with new “longevity” testing program
Toronto-based digital health company Felix is expanding to offer ongoing health monitoring, aimed at increasing “longevity,” as Canadian patients seek options for preventative healthcare. Felix is part of a growing list of Canadian telehealth startups that make convenience and discretion part of their draw. The company’s new longevity platform includes an annual test and ongoing monitoring […]